Physician profile
Mark C Nuguid
NPI 1447785290
$3,864.05
in general payments reported to CMS, 2019-2025
22 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.84 · 2022: $542 · 2023: $819 · 2024: $711 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.57 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $746.26 | 2022-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $499.34 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Gilead Sciences, INC. | $472.95 | 2021-2025 | Epclusa, Biktarvy |
| Astellas Pharma US INC | $420.24 | 2023-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $253.76 | 2023-2025 | Zevtera, Xerava, Xacduro |
| Insmed, INC. | $237.52 | 2023-2025 | Arikayce, Brinsupri |
| Shionogi INC | $232.79 | 2021-2025 | Fetroja |
| Abbvie INC. | $210.74 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $190.13 | 2022-2025 | Rebyota |
| Theratechnologies INC. | $166.44 | 2023-2025 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $71.08 | 2023-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $69.06 | 2023-2024 | Livtencity |
| Csl Behring | $53.86 | 2025 | Hizentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.54 | 2022-2025 | Xifaxan |
| Cormedix INC. | $35.51 | 2025 | Defencath |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $32.59 | 2022 | |
| Aimmune Therapeutics, INC. | $25.70 | 2025 | Vowst |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Thinprep 2000 Processor, Aptima |
| Melinta Therapeutics, LLC | $21.80 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Electromed, INC. | $19.96 | 2022 | |
| Janssen Biotech, INC. | $19.25 | 2022 | |
| Napo Pharmaceuticals INC | $15.29 | 2023 | Mytesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nuguid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.